Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Show more...
FAQ
Chemomab Therapeutics 今天的股價是多少?▼
CMMB.BOATS 目前價格為 $2.18 USD,過去 24 小時上漲了 +0%。在圖表上更密切關注 Chemomab Therapeutics 股價表現。
Chemomab Therapeutics 的股票代號是什麼?▼
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Chemomab Therapeutics 的股票以代號 CMMB.BOATS 進行交易。
Chemomab Therapeutics 去年的營收是多少?▼
Chemomab Therapeutics 去年的營收為 0USD。
Chemomab Therapeutics 去年的淨利是多少?▼
CMMB.BOATS 去年的淨收益為 -27.89MUSD。
Chemomab Therapeutics 有多少名員工?▼
截至 April 01, 2026,公司共有 20 名員工。
Chemomab Therapeutics 位於哪個產業?▼
Chemomab Therapeutics從事於Health Care產業。
Chemomab Therapeutics 何時完成拆股?▼
Chemomab Therapeutics 最近沒有進行任何拆股。
Chemomab Therapeutics 的總部在哪裡?▼
Chemomab Therapeutics 的總部位於 US 的 Tel Aviv。